BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, July 6, 2026
Home » Topics » Financings

Financings
Financings RSS Feed RSS

Financings for Oct. 24, 2023

Oct. 24, 2023
Biopharmas in Asia-Pacific raising money in public or private financings: Athersys, Healios.
Read More
DNA in drug capsules

$85M series A fortifies Rampart push in DNA-based therapies

Oct. 24, 2023
By Randy Osborne
Emerging from stealth mode, Rampart Bioscience Inc. pulled down $85 million in series A money for work on DNA-based drugs – a round that was led by Forbion with participation from seed investor Orbimed and new backers RA Capital Management and Healthcap.
Read More

Financings for Oct. 24, 2023

Oct. 24, 2023
Biopharmas raising money in public or private financings, including: Cargo, Coeptis, Dermbiont, Ensysce, Invea, Lipella, Lygenesis, Orbimed, Ultragenyx.
Read More
Science and medicine icons with head made of computer code

Phasev raises $15M for machine learning tool that optimizes clinical trials

Oct. 24, 2023
By Shani Alexander
Phasev Inc. has raised $15 million in a funding round that will allow the company to further develop its machine learning (ML) technology that aims to revolutionize clinical trial design, execution and analysis. The funding round was led by Viola Ventures and Exor Ventures and included participation from Lionbird and a group of prominent angel investors.
Read More

Financings for Oct. 24, 2023

Oct. 24, 2023
Med-tech firms raising money in public or private financings, including: Orbimed.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Med-tech firms raising money in public or private financings, including: Aurora.
Read More

Financings for Oct. 23, 2023

Oct. 23, 2023
Biopharmas raising money in public or private financings, including: Aligos, Applied Molecular Transport, Cyclo, Harpoon.
Read More

Abivax gains US listing, pads coffers with $236M in Nasdaq IPO

Oct. 20, 2023
By Jennifer Boggs
Abivax SA’s debut on the U.S. market received a somewhat chilly reception Oct. 20, as the firm priced on the low end of its proposed range and ended the first day of trading in the red. But the company managed to pull in about $235.8 million in gross proceeds, the majority of which will support late-stage efforts for obefazimod, an oral candidate with a novel mechanism of action it hopes to advance in the lucrative inflammatory bowel disease space.
Read More

Financings for Oct. 20, 2023

Oct. 20, 2023
Biopharmas raising money in public or private financings, including: Arcutis, Adial, Talaris, Tourmaline.
Read More

Financings for Oct. 19, 2023

Oct. 19, 2023
Biopharmas raising money in public or private financings, including: Abivax, Ultragenyx.
Read More
Previous 1 2 … 251 252 253 254 255 256 257 258 259 … 681 682 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 2, 2026.
  • CINP 2026: Prenatal and adolescent stress shape brain vulnerability

    BioWorld Science
    Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
  • Ontrack Therapeutics divulges compounds for neurodegenerative diseases

    BioWorld Science
    Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
  • IPO puzzle pieces

    Neuracle eyes Shanghai IPO as global BCI funding surges

    BioWorld
    Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
  • Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists

    BioWorld Science
    Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing